Basics |
Company: |
Halozyme Therapeutics, Inc. |
IPO Date: |
March 16, 2004 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$7.42B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.36 | 2.17%
|
Avg Daily Range (30 D): |
$0.62 | 1.16%
|
Avg Daily Range (90 D): |
$0.81 | 1.55%
|
Institutional Daily Volume |
Avg Daily Volume: |
.93M |
Avg Daily Volume (30 D): |
1M |
Avg Daily Volume (90 D): |
1.24M |
Trade Size |
Avg Trade Size (Sh.): |
112 |
Avg Trade Size (Sh.) (30 D): |
56 |
Avg Trade Size (Sh.) (90 D): |
61 |
Institutional Trades |
Total Inst.Trades: |
8,193 |
Avg Inst. Trade: |
$2.55M |
Avg Inst. Trade (30 D): |
$2.96M |
Avg Inst. Trade (90 D): |
$3.04M |
Avg Inst. Trade Volume: |
.08M |
Avg Inst. Trades (Per Day): |
3 |
Market Closing Trades |
Avg Closing Trade: |
$4.65M |
Avg Closing Trade (30 D): |
$9.48M |
Avg Closing Trade (90 D): |
$11.3M |
Avg Closing Volume: |
147.73K |
|
|
|
|
Financials |
|
TTM |
Q3 2024 |
Q2 2024 |
Basic EPS
|
$3.07
|
$1.08
|
$.73
|
Diluted EPS
|
$3.02
|
$1.05
|
$.72
|
Revenue
|
$ 947.36M
|
$ 290.08M
|
$ 231.35M
|
Gross Profit
|
$ 777.7M
|
$ 240.66M
|
$ 191.75M
|
Net Income / Loss
|
$ 392.47M
|
$ 137.01M
|
$ 93.25M
|
Operating Income / Loss
|
$ 477.01M
|
$ 163.2M
|
$ 117.24M
|
Cost of Revenue
|
$ 169.66M
|
$ 49.43M
|
$ 39.61M
|
Net Cash Flow
|
$ -119.91M
|
$ -33.55M
|
$ 23.24M
|
PE Ratio
|
19.45
|
|
|
|